Biotesserae Camunity develops a nanobody-based platform designed for canine cancer treatments.
Biotesserae Camunity is a nanobody-based platform for the production of a new class of therapeutics for canine cancer. The company was formed by Chris Cebra, chair of the Department of Clinical Sciences, and colleagues Shay Bracha, Dan Mourich, and Carl Ruby.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 6, 2022 | Pre-seed | $100K | 1 |
EXPERT DOJO
|
— | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
EXPERT DOJO
|
Yes | Pre-seed |